Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CERO NASDAQ:ELAB NASDAQ:ENVB NASDAQ:PTPI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCEROCERo Therapeutics$7.58+2.2%$9.51$6.71▼$895.40$2.86M0.48105,473 shs36,512 shsELABPMGC$2.28-1.3%$2.26$1.95▼$660.80$3.18M0.13177,550 shs53,791 shsENVBEnveric Biosciences$1.31-0.8%$1.27$1.01▼$11.55$3.26M0.54192,885 shs82,840 shsPTPIPetros Pharmaceuticals$0.03+3.7%$0.04$0.02▼$16.25$966K1.565.64 million shs361,189 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCEROCERo Therapeutics-9.84%-14.71%-22.38%-58.32%-98.24%ELABPMGC0.00%+0.87%+5.96%+2.21%-99.63%ENVBEnveric Biosciences-3.65%+3.13%+5.60%-4.35%-81.63%PTPIPetros Pharmaceuticals+1.01%+3.82%-0.33%-97.79%-99.71%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCEROCERo Therapeutics3.4613 of 5 stars3.74.00.00.01.40.80.0ELABPMGC0.6975 of 5 stars0.04.00.00.01.90.00.6ENVBEnveric Biosciences2.5292 of 5 stars3.52.00.00.03.00.01.3PTPIPetros PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCEROCERo Therapeutics 3.33Buy$45.00493.67% UpsideELABPMGC 0.00N/AN/AN/AENVBEnveric Biosciences 3.00Buy$10.00663.36% UpsidePTPIPetros Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest PTPI, CERO, ENVB, and ELAB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/23/2025CEROCERo TherapeuticsD Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy6/23/2025CEROCERo TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$30.005/30/2025CEROCERo TherapeuticsD Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/30/2025CEROCERo TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold5/19/2025CEROCERo TherapeuticsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$60.00(Data available from 7/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCEROCERo TherapeuticsN/AN/AN/AN/A($41.98) per shareN/AELABPMGC$1.71M1.84N/AN/A$11.53 per share0.20ENVBEnveric BiosciencesN/AN/AN/AN/A$2.35 per shareN/APTPIPetros Pharmaceuticals$5.11M0.19N/AN/A$4.04 per share0.01Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCEROCERo Therapeutics-$8.30MN/A0.00∞N/AN/AN/A-199.71%8/13/2025 (Estimated)ELABPMGC-$6.25M-$433.87N/A∞N/AN/A-77.80%-59.17%8/13/2025 (Estimated)ENVBEnveric Biosciences-$9.57M-$38.38N/AN/AN/AN/A-250.28%-195.57%8/11/2025 (Estimated)PTPIPetros Pharmaceuticals-$8.16M-$60.87N/A∞N/AN/A-78.22%-23.50%N/ALatest PTPI, CERO, ENVB, and ELAB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025N/ACEROCERo TherapeuticsN/A-$31.80N/A-$1.59N/AN/A5/15/2025Q1 2025PTPIPetros PharmaceuticalsN/A-$8.46N/A-$9.37N/AN/A5/14/2025Q1 2025ELABPMGCN/A-$2.90N/A-$2.95N/AN/A5/14/2025Q1 2025ENVBEnveric Biosciences-$3.45-$1.22+$2.23-$1.22N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCEROCERo TherapeuticsN/AN/AN/AN/AN/AELABPMGCN/AN/AN/AN/AN/AENVBEnveric BiosciencesN/AN/AN/AN/AN/APTPIPetros PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCEROCERo TherapeuticsN/A0.730.73ELABPMGCN/A8.978.97ENVBEnveric BiosciencesN/A4.084.08PTPIPetros Pharmaceuticals1.580.850.74Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCEROCERo Therapeutics29.64%ELABPMGC22.22%ENVBEnveric Biosciences13.82%PTPIPetros Pharmaceuticals12.34%Insider OwnershipCompanyInsider OwnershipCEROCERo Therapeutics12.72%ELABPMGC0.60%ENVBEnveric Biosciences1.10%PTPIPetros Pharmaceuticals8.23%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCEROCERo Therapeutics8390,000337,000N/AELABPMGC181.38 million1.37 millionN/AENVBEnveric Biosciences202.47 million2.45 millionNot OptionablePTPIPetros Pharmaceuticals2031.16 million9.93 millionNot OptionablePTPI, CERO, ENVB, and ELAB HeadlinesRecent News About These CompaniesPetros Pharmaceuticals, Inc.: Petros Pharmaceuticals Announces Deconsolidation of Metuchen Pharmaceuticals Subsidiary, Strengthening its Balance Sheet and Improving the Company ...June 26, 2025 | finanznachrichten.dePetros Pharmaceuticals to deconsolidate subsidiary to improve financesJune 26, 2025 | investing.comPetros Pharmaceuticals Announces Deconsolidation of Metuchen Pharmaceuticals Subsidiary, Strengthening its Balance Sheet and Improving the Company's Equity Position | MorningstarJune 26, 2025 | morningstar.comMPetros Pharmaceuticals, Inc. (PTPI) - Yahoo FinanceJune 26, 2025 | finance.yahoo.comPetros Pharmaceuticals Inc News (PTPI) - Investing.comJune 26, 2025 | investing.comPetros Pharmaceuticals Announces Deconsolidation of Metuchen Pharmaceuticals Subsidiary, Strengthening its Balance Sheet and Improving the Company's Equity PositionJune 25, 2025 | accessnewswire.comAPetros Pharmaceuticals to appeal Nasdaq delisting decisionMay 23, 2025 | uk.investing.comPetros Pharmaceuticals Announces Transition from NASDAQ to OTC MarketsMay 21, 2025 | accessnewswire.comAPetros Pharmaceuticals, Inc.: Petros Pharmaceuticals Partners with Innolitics, a Leading Software-as-a-Medical-Device DeveloperMay 20, 2025 | finanznachrichten.dePetros Pharmaceuticals Partners with Innolitics, a Leading Software-as-a-Medical-Device DeveloperMay 20, 2025 | accessnewswire.comAPetros Pharmaceuticals Strengthens Partnership with Market Leading Big Data Provider Implementing Key Enhancements to its AI PlatformMay 6, 2025 | accessnewswire.comAPetros Proprietary Technology Platform Aligns with April 15, 2025 President Trump Executive Order Advancing Rx-to-OTC Reclassification ReformsApril 29, 2025 | accessnewswire.comAPetros Pharmaceuticals, Inc.: Petros Pharmaceuticals to Partner with Renowned Big Data Provider to Enable Rx-to-OTC Switch Across Multiple IndicationsMarch 20, 2025 | finanznachrichten.dePetros Pharmaceuticals enters collaboration with big data, analytics firmMarch 20, 2025 | msn.comPetros Pharmaceuticals to Partner with Renowned Big Data Provider to Enable Rx-to-OTC Switch Across Multiple IndicationsMarch 20, 2025 | accessnewswire.comAPetros Pharmaceuticals, Inc.: Petros Pharmaceuticals' Proprietary Technology Demonstrates Positive Data in Pivotal StudyFebruary 27, 2025 | finanznachrichten.dePetros Pharmaceuticals announces top-line results of expanded App Comp studyFebruary 25, 2025 | markets.businessinsider.comPetros Pharmaceuticals' Proprietary Technology Demonstrates Positive Data in Pivotal StudyFebruary 25, 2025 | accessnewswire.comAPetros Pharmaceuticals prices 40M shares at 24c in public offeringFebruary 18, 2025 | markets.businessinsider.comPetros Pharmaceuticals, Inc.: Petros Pharmaceuticals Announces Pricing of $9.6 Million Public Offering of Common Stock and WarrantsFebruary 18, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimePTPI, CERO, ENVB, and ELAB Company DescriptionsCERo Therapeutics NASDAQ:CERO$7.58 +0.16 (+2.16%) Closing price 04:00 PM EasternExtended Trading$7.72 +0.15 (+1.91%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.PMGC NASDAQ:ELAB$2.28 -0.03 (-1.30%) Closing price 04:00 PM EasternExtended Trading$2.34 +0.06 (+2.68%) As of 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Elevai Labs, Inc., a skincare development company, designs, manufactures, and markets skincare products. Its products include Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. The company was formerly known as Reactive Medical Labs Inc. and changed its name to Elevai Labs, Inc. in December 2021. Elevai Labs, Inc. was incorporated in 2020 and is based in Newport Beach, California.Enveric Biosciences NASDAQ:ENVB$1.31 -0.01 (-0.76%) Closing price 04:00 PM EasternExtended Trading$1.28 -0.03 (-2.29%) As of 06:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida.Petros Pharmaceuticals NASDAQ:PTPI$0.03 +0.00 (+3.68%) As of 03:59 PM EasternPetros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Intel's Turnaround Gains Credibility With Strong Q2 Report Qualcomm's Next Gear: A Growth Story Wall Street Might Be Missing Krispy Kreme: A Meme Stock Sugar Rush or a Sustainable Treat? From Zero to Hero? Why GoPro's Rally Could Be More Than It Seems CrowdStrike Scores Big With Gartner, But Valuation Is Stretched ServiceNow: The 2nd Wave of AI Spending Is Here Tractor Supply Revs Up on Forecast Hike and Bullish Signals A Smokin’ Hot Entry Point for Chipotle Stock Opens in Q3 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
